Cannabis and Alzheimer’s disease

See also:

Marijuana for Alzheimers

Active ingredient in marijuana may help preserve brain function

A puff a day might keep Alzheimer’s away

The following is written by Dr. Robert Melamede and comes from here.

Alzheimer’s disease is a neuro-degenerative condition for which cannabis and cannabinoid therapies show promise, both for treating the symptoms and the underlying disease.

Cannabis

Alzheimer’s disease is widely held to be associated with oxidative stress due, in part, to the membrane action of beta-amyloid peptide aggregates.  A laboratory study published in 2004 indicates that one of the cannabis plant’s primary components, cannabidiol (CBD), exerts a combination of neuroprotective, anti-oxidative and antiapoptotic effects by inhibiting the release of the toxic beta-amyloid peptide.

Another cannabinoid, THC, has also has been shown to reduce the agitation common to Alzheimer’s sufferers, according to findings presented in 2003 at the American Society of Consultant Pharmacists’ 34th annual meeting.  Agitation is the most common behavioral management problem in patients with Alzheimer’s and affects an estimated 75 percent of people with the disease.  It may lead to a variety of symptoms ranging from physical and/or verbal abusive postures, physically non-aggressive conduct including pacing and restlessness, as well as verbally disturbed behaviors such as screaming and repetitive requests for attention.

This study and the Institutes of Medicine report also show THC to be effective in combating the anorexia or wasting syndrome common to Alzheimer’s sufferers, since food refusal is a common problem in patients who suffer from Alzheimer’s type dementia. The appetite-stimulation properties of cannabis are some of the most well-established in clinical research.122

This new research on cannabis and Alzheimer’s disease, coupled with the extensive work done on other neuroprotective qualities of cannabis and its components, indicates that cannabis may become the source of the most effective treatments for battling the Central Nervous System diseases that afflict millions of elderly Americans.

 

Raphael Mechoulam & Robert Melamede – Cannabis Therapeutics Conference

Folks,
This is state of the art information. Please disseminate widely. If you forward to all your MD and RN service providers and friends that would be a plus.

Cannabinoid System in Neuroprotection – Raphael Mechoulam (part 1 of 5)

At 2004 Cannabis Therapeutics Conference, Dr. Mechoulam, Professor at Hebrew University in Jerusalem, describes the role of Cannabinoids as anti-inflammatory for arthritis, as neuroprotectant for brain injury and as a possible treatment for PTSD. Dr. Mechoulam first isolated THC in 1964. Conference hosted by Patients Out of Time.

Cannabinoid System in Neuroprotection – Raphael Mechoulam (part 5 of 5)

(continued from above)


Holistic Biochemistry of Cannabinoids by Robert Melamede (part 1 of 5)

At 2004 Cannabis Therapeutics Conference, Dr. Melamede, University of Colorado, explains how the Endocannabinoid System functions as a “Global Homeostatic Regulator”, balancing several organ systems. He hypothesises that, “Free Radicals are the Friction of Life. Endocannabinoids are the Oil of Life.” Conference hosted by Patients Out of Time.

Holistic Biochemistry of Cannabinoids by Robert Melamede (part 3 of 5)

(continued from above)

Holistic Biochemistry of Cannabinoids by Robert Melamede (part 4 of 5)

(continued from above)

Share

Cannabis Compounds Reduce Multi-Drug Resistant Infections

Study Says Cannabinoids Show “Exceptional” Antibacterial Activity Against MRSA

(Source: CannaZine) Cannabis Science, Inc. (OTCBB: GFON)marijuana.medical

Dr. Robert Melamede, PhD., Director and Chief Science Officer, reported to the Board on the current state of research into the use of natural plant cannabinoids to reduce the spread of drug-resistant bacteria, including methicillin-resistant Staphyloccus aureus (MRSA), and the prospects for development of topical whole-cannabis treatments.

According to studies published in the Journal of the American Medical Association and by the Center for Disease Control in 2007, MRSA is responsible for more than 18,500 hospital-stay related deaths each year, and increased direct healthcare costs of as much as $9.7 billion.

Dr. Melamede stated, “Research into use of whole cannabis extracts and multi-cannabinoid compounds has provided the scientific rationale for medical marijuana’s efficacy in treating some of the most troubling diseases mankind now faces, including infectious diseases such as the flu and HIV, autoimmune diseases such as ALS (Lou Gehrig’s Disease), multiple sclerosis, arthritis, and diabetes, neurological conditions such as Alzheimer’s, stroke and brain injury, as well as numerous forms of cancer. One common element of these diseases is that patients often suffer extended hospital stays, risking development of various Staphyloccus infections including MRSA. A topical, whole-cannabis treatment for these infections is a functional complement to our cannabis extract-based lozenge.”Investigators at Italy’s Universita del Piemonte Orientale and Britain’s University of London, School of Pharmacy reported in the Journal of Natural Products that five cannabinoids – THC, CBD, CBG, CBC, and CBN – “showed potent antibacterial activity” and “exceptional” antibacterial activity against two epidemic MRSA occurring in UK hospitals.

The authors concluded: “Although the use of cannabinoids as systemic antibacterial agents awaits rigorous clinical trials, … their topical application to reduce skin colonization by MRSA seems promising. … Cannabis sativa … represents an interesting source of antibacterial agents to address the problem of multidrug resistance in MRSA and other pathogenic bacteria.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934.

A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

Some or all of the events or results anticipated by these forward-looking statements may not occur.

Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs.

Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Inc.
Steven W. Kubby, 888-889-0888
President & CEO
www.cannabisscience.com

Share